{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:32:39Z","timestamp":1789475559139,"version":"build-2803163510"},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["mcpiqojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.mayocpiqo.2021.11.009","type":"journal-article","created":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T18:03:28Z","timestamp":1640714608000},"page":"69-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies"],"prefix":"10.1016","volume":"6","author":[{"given":"John B.","family":"Hagan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Ender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit D.","family":"Divekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanai","family":"Pongdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Rank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mayocpiqo.2021.11.009_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.tibtech.2018.05.014","article-title":"The increasingly human and profitable monoclonal antibody market","volume":"37","author":"Grilo","year":"2019","journal-title":"Trends Biotechnol"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2021.11.009_bib7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4161\/mabs.19931","article-title":"Marketed therapeutic antibodies compendium","volume":"4","author":"Reichert","year":"2012","journal-title":"MAbs"},{"issue":"D1","key":"10.1016\/j.mayocpiqo.2021.11.009_bib8","doi-asserted-by":"crossref","first-page":"D1080","DOI":"10.1093\/nar\/gkv1192","article-title":"WITHDRAWN--a resource for withdrawn and discontinued drugs","volume":"44","author":"Siramshetty","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2021.11.009_bib9","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/nbt.4305","article-title":"Biopharmaceutical benchmarks 2018","volume":"36","author":"Walsh","year":"2018","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.mayocpiqo.2021.11.009_bib17","series-title":"The Future of Drug Safety: Promoting and Protecting the Health of the Public","year":"2007"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2021.11.009_bib18","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/archinte.161.5.706","article-title":"How much information about adverse effects of medication do patients want from physicians?","volume":"161","author":"Ziegler","year":"2001","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2021.11.009_bib19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2021.11.009_bib20","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2021.11.009_bib21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2021.11.009_bib22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2021.11.009_bib23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamaneurol.2019.2670","article-title":"Progressive multifocal leukoencephalopathy incidence and risk stratification among natalizumab users in France","volume":"77","author":"Vukusic","year":"2020","journal-title":"JAMA Neurol"},{"issue":"18","key":"10.1016\/j.mayocpiqo.2021.11.009_bib24","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1001\/jama.2017.5150","article-title":"postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010","volume":"317","author":"Downing","year":"2017","journal-title":"JAMA"}],"container-title":["Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454821001661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454821001661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:10:32Z","timestamp":1762870232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542454821001661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2542454821001661"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2021.11.009","relation":{},"ISSN":["2542-4548"],"issn-type":[{"value":"2542-4548","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings: Innovations, Quality & Outcomes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2021.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research.","name":"copyright","label":"Copyright"}]}}